AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEURIZON THERAPEUTICS LTD

0.084

0.000

Volume:500.92K

Turnover:41.35K

Market Cap:58.68M

PE:-2.84

High:0.084

Open:0.084

Low:0.081

Close:0.084

52wk High:0.185

52wk Low:0.076

Shares:698.63M

Float Shares:351.37M

Volume Ratio:0.56

T/O Rate:0.14%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.030

EPS(LYR):-0.034

ROE:-147.09%

ROA:-60.21%

PB:7.08

PE(LYR):-2.47

Loading ...

Overview Company News Filings

Neurizon Therapeutics Chief Executive Officer Resigns, Shares Down 13%

MT Newswires Live

Neurizon Therapeutics - Sergio Duchini to Assume Role of Executive Chair Until New CEO Appointed

THOMSON REUTERS

Neurizon Therapeutics - Michael Thurn Resigns as Managing Director and CEO

THOMSON REUTERS

Neurizon Says Pre-Clinical Data Supports Potential of Drug Candidate for Neurodegenerative Disease

MT Newswires Live

Neurizon Doses First Patient With NUZ-001 in HEALEY ALS Platform Trial Regimen I

BUZZ-Australia's Neurizon Therapeutics rises as HY loss narrows, revenue rises

BRIEF-Neurizon Therapeutics Posts Loss For Half Year Attributable Of A$5.5 Million

Neurizon Therapeutics Ltd - Hy Other Income a$6 Mln

THOMSON REUTERS

Neurizon Therapeutics Ltd - Loss for Half Year Attributable a$5.5 Mln

THOMSON REUTERS

Neurizon Therapeutics Ltd-Change of Director's Interest Notice

THOMSON REUTERS

Neurizon Therapeutics Ltd-Neurizon Completes Entitlement Offer

THOMSON REUTERS

Neurizon Therapeutics Ltd-Change of Director's Interest Notice

THOMSON REUTERS

BRIEF-Neurizon Therapeutics Secures Registered Trademark Protection For Neurizon® Across All Priority Global Markets

Neurizon Therapeutics Ltd - Secured Registered Trademark Protection for Neurizon® Across All Priority Global Markets

THOMSON REUTERS

BUZZ-Neurizon Therapeutics falls after US FDA denies fast track designation request

Neurizon Therapeutics Ltd - Updates on Nuz-001 Development for ALS

THOMSON REUTERS

Neurizon Therapeutics Ltd - US FDA Denies Fast Track Designation for Nuz-001

THOMSON REUTERS

BRIEF-Neurizon Therapeutics Says Firm Commitments To Raise A$7.1 Million Via Placement

BUZZ-Australia's Neurizon Therapeutics drops to 2-year low on discounted placement

Neurizon Therapeutics Ltd - Firm Commitments to Raise a$7.1 Mln via Placement at a$0.08 per Share

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NUZ.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NUZ.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","market":"AU","secType":"STK","nameCN":"NEURIZON THERAPEUTICS LTD","latestPrice":0.084,"timestamp":1773983520000,"preClose":0.084,"halted":0,"volume":500920,"delay":0,"changeRate":0,"nameEN":"NEURIZON THERAPEUTICS LTD","floatShares":351374969,"shares":698628681,"eps":-0.029543,"marketStatus":"Not Yet Opened","change":0,"latestTime":"03-20 16:12:00 AEDT","open":0.084,"high":0.084,"low":0.081,"amount":41354,"amplitude":0.035714,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.029543,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1774220400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.084,"openAndCloseTimeList":[[1773961200000,1773982800000]],"volumeRatio":0.5562536672335026,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NUZ.AU","preClose":0.084,"auctionPrice":0.084,"auctionVolume":13043,"auctionTime":1774210181072,"referenceTime":1773912604089,"auction":1,"marketStatus":"盘前竞价","timestamp":1774210181072}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","floatShares":351374969,"roa":"-60.21%","roe":"-147.09%","lyrEps":-0.034045,"volumeRatio":0.5562536672335026,"shares":698628681,"dividePrice":0,"high":0.084,"amplitude":0.035714,"preClose":0.084,"low":0.081,"week52Low":0.076,"pbRate":"7.08","psRate":"9.81","week52High":0.185,"institutionHeld":0,"latestPrice":0.084,"eps":-0.029543,"divideRate":0,"volume":500920,"delay":0,"ttmEps":-0.029543,"open":0.084,"prevYearClose":0.085,"prevWeekClose":0.084,"prevMonthClose":0.092,"prevQuarterClose":0.085,"fiveDayClose":0.096,"twentyDayClose":0.095,"sixtyDayClose":0.11,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NUZ.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NUZ.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NUZ.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2619484594","title":"Neurizon Therapeutics Chief Executive Officer Resigns, Shares Down 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619484594","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619484594?lang=en_us&edition=fundamental","pubTime":"2026-03-16 08:40","pubTimestamp":1773621622,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  said Michael Thurn has resigned as managing director and chief executive officer, stepping down from his executive responsibilities from March 16, with his contractual notice period concluding in July 2026, according to a Monday Australian bourse filing.Thurn will continue to serve as a non-executive director until the completion of his notice period, the filing added.The company said Sergio Duchini will assume the role of interim executive chair until a suitable chief executive is appointed, while a global search for a new CEO is underway with the assistance of executive search firm Coulter Partners.The company's shares fell 13% in recent Monday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","BK4007","BK4539","BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2619748557","title":"Neurizon Therapeutics - Sergio Duchini to Assume Role of Executive Chair Until New CEO Appointed","url":"https://stock-news.laohu8.com/highlight/detail?id=2619748557","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619748557?lang=en_us&edition=fundamental","pubTime":"2026-03-16 05:20","pubTimestamp":1773609614,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260315:nFWN40200M:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2619572485","title":"Neurizon Therapeutics  - Michael Thurn Resigns as Managing Director and CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2619572485","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619572485?lang=en_us&edition=fundamental","pubTime":"2026-03-16 05:20","pubTimestamp":1773609614,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260315:nFWN40200M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2617591498","title":"Neurizon Says Pre-Clinical Data Supports Potential of Drug Candidate for Neurodegenerative Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2617591498","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617591498?lang=en_us&edition=fundamental","pubTime":"2026-03-05 11:30","pubTimestamp":1772681410,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  said its treatment candidate, NUZ-001, and major active metabolite NUZ-001 sulfone showed in-vivo biological activity, based on data from ongoing pre-clinical studies, according to a Thursday Australian bourse filing.The company is evaluating NUZ-001 in various Huntington's disease models and showed disease-dependent restoration of brain-derived neurotrophic factor levels and enhanced autophagic markers, among others, the filing said.Huntington's disease is a fatal neurodegenerative disorder caused by a mutation in the HTT gene, which produces a toxic form of the huntingtin protein that damages neurons.Drug exposure studies confirmed that both NUZ-001 and NUZ-001 sulfone were readily taken up in zebrafish, with both compounds demonstrating biological activity in vivo, per the filing. The restorative effects of NUZ-001 and NUZ-001 sulfone on brain-derived neurotrophic factor levels were shown to be selective to the HTT knockdown condition and were not observed in ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2614132073","title":"Neurizon Doses First Patient With NUZ-001 in HEALEY ALS Platform Trial Regimen I","url":"https://stock-news.laohu8.com/highlight/detail?id=2614132073","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614132073?lang=en_us&edition=fundamental","pubTime":"2026-02-27 04:35","pubTimestamp":1772138102,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics Ltd. reported that the first participant has been enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial for amyotrophic lateral sclerosis. The company said the regimen is a 36-week randomized, double-blind, placebo-controlled adaptive Phase 2/3 study expected to enroll about 160 ALS participants across U.S. clinical sites, with participants randomized 3:1 to daily NUZ-001 at 10 mg/kg or placebo, followed by a 36-week active treatment extension. Neurizon also cited results from its Phase 1 program in 12 people with ALS, stating NUZ-001 was safe and well-tolerated and showed preliminary signals of efficacy, and said enrollment is expected to complete in the second half of calendar year 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL81bnvH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2614963773","title":"BUZZ-Australia's Neurizon Therapeutics rises as HY loss narrows, revenue rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2614963773","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614963773?lang=en_us&edition=fundamental","pubTime":"2026-02-25 10:22","pubTimestamp":1771986156,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neurizon Therapeutics rises as HY loss narrows, revenue rises** Shares of Australia's Neurizon Therapeutics NUZ.AX rise as much as 3.1% to A$0.1, their highest level since February 19** Stock on track to record its third straight session of gains, if the trend holds** Biotech company posts HY loss attributable to A$5.5 million , compared with a loss of A$7.3 million in the prior corresponding period** Posts increase in HY revenue to A$6 million from A$1.8 million last year** Stock has risen 14.1% this year, including session moves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL4N3ZL06F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2614361778","title":"BRIEF-Neurizon Therapeutics Posts Loss For Half Year Attributable Of A$5.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614361778","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614361778?lang=en_us&edition=fundamental","pubTime":"2026-02-25 09:46","pubTimestamp":1771983978,"startTime":"0","endTime":"0","summary":"BRIEF-Neurizon Therapeutics Posts Loss For Half Year Attributable Of A$5.5 MillionFeb 25 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX:LOSS FOR HALF YEAR ATTRIBUTABLE A$5.5 MILLIONHY  OTHER INCOME A$6 MILLIONFurther company coverage: NUZ.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZK1FD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2614729197","title":"Neurizon Therapeutics Ltd - Hy  Other Income a$6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2614729197","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614729197?lang=en_us&edition=fundamental","pubTime":"2026-02-25 06:52","pubTimestamp":1771973552,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nFWN3ZK1FD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2614291927","title":"Neurizon Therapeutics Ltd -  Loss for Half Year Attributable a$5.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2614291927","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614291927?lang=en_us&edition=fundamental","pubTime":"2026-02-25 06:52","pubTimestamp":1771973552,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nFWN3ZK1FD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2608128842","title":"Neurizon Therapeutics Ltd-Change of Director's Interest Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2608128842","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608128842?lang=en_us&edition=fundamental","pubTime":"2026-02-03 14:53","pubTimestamp":1770101598,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nTUE8LTS7H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2606938224","title":"Neurizon Therapeutics Ltd-Neurizon Completes Entitlement Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2606938224","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606938224?lang=en_us&edition=fundamental","pubTime":"2026-01-27 06:56","pubTimestamp":1769468199,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nTUE6SWHXC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2605448501","title":"Neurizon Therapeutics Ltd-Change of Director's Interest Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2605448501","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605448501?lang=en_us&edition=fundamental","pubTime":"2026-01-23 06:08","pubTimestamp":1769119728,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nTUE62QT70:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2604152626","title":"BRIEF-Neurizon Therapeutics Secures Registered Trademark Protection For Neurizon® Across All Priority Global Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2604152626","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604152626?lang=en_us&edition=fundamental","pubTime":"2026-01-20 09:20","pubTimestamp":1768872022,"startTime":"0","endTime":"0","summary":"BRIEF-Neurizon Therapeutics Secures Registered Trademark Protection For Neurizon Across All Priority Global MarketsJan 20  - Neurizon Therapeutics Ltd NUZ.AX:SECURED REGISTERED TRADEMARK PROTECTION FOR NEURIZON ACROSS ALL PRIORITY GLOBAL MARKETSFurther company coverage: NUZ.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nFWN3YK0KL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2604815662","title":"Neurizon Therapeutics Ltd - Secured Registered Trademark Protection for Neurizon® Across All Priority Global Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2604815662","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604815662?lang=en_us&edition=fundamental","pubTime":"2026-01-20 06:49","pubTimestamp":1768862945,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nFWN3YK0KL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2600034250","title":"BUZZ-Neurizon Therapeutics falls after US FDA denies fast track designation request","url":"https://stock-news.laohu8.com/highlight/detail?id=2600034250","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600034250?lang=en_us&edition=fundamental","pubTime":"2026-01-02 07:40","pubTimestamp":1767310806,"startTime":"0","endTime":"0","summary":"BUZZ-Neurizon Therapeutics falls after US FDA denies fast track designation request** Shares of Australia's Neurizon Therapeutics NUZ.AX fall as much as 5.9% to A$0.08, their lowest level since November 23, 2023** Marks steepest intraday pct fall since December 23** Biotech company says the U.S. Food and Drug Administration denies its request for Fast Track Designation** Request was for its investigational new treatment for Amyotrophic Lateral Sclerosis, NUZ-001  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260101:nL6N3Y206B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2600031619","title":"Neurizon Therapeutics Ltd - Updates on Nuz-001 Development for ALS","url":"https://stock-news.laohu8.com/highlight/detail?id=2600031619","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600031619?lang=en_us&edition=fundamental","pubTime":"2026-01-02 05:47","pubTimestamp":1767304037,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260101:nTUE4HMJT5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2600031611","title":"Neurizon Therapeutics Ltd - US FDA Denies Fast Track Designation for Nuz-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2600031611","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600031611?lang=en_us&edition=fundamental","pubTime":"2026-01-02 05:47","pubTimestamp":1767304037,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260101:nTUE4HMJT5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2593545420","title":"BRIEF-Neurizon Therapeutics Says Firm Commitments To Raise A$7.1 Million Via Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2593545420","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593545420?lang=en_us&edition=fundamental","pubTime":"2025-12-23 09:13","pubTimestamp":1766452424,"startTime":"0","endTime":"0","summary":"BRIEF-Neurizon Therapeutics Says Firm Commitments To Raise A$7.1 Million Via PlacementDec 23 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX:FIRM COMMITMENTS TO RAISE A$7.1 MILLION VIA PLACEMENT AT A$0.08 PER SHAREFurther company coverage: NUZ.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XS0TA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2593925459","title":"BUZZ-Australia's Neurizon Therapeutics drops to 2-year low on discounted placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2593925459","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593925459?lang=en_us&edition=fundamental","pubTime":"2025-12-23 08:03","pubTimestamp":1766448209,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neurizon Therapeutics drops to 2-year low on discounted placement** Shares of Australia's Neurizon Therapeutics NUZ.AX slump as much as 23.6% to A$0.084, their lowest since late Novem","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nL6N3XT000:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2593455719","title":"Neurizon Therapeutics Ltd -  Firm Commitments to Raise a$7.1 Mln via Placement at a$0.08 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2593455719","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593455719?lang=en_us&edition=fundamental","pubTime":"2025-12-23 06:50","pubTimestamp":1766443838,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nFWN3XS0TA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":54,"code":"91000000","status":"200"}]}}